ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 19 of 45
Up
УЖМБС 2023, 8(1): 146–150
https://doi.org/10.26693/jmbs08.01.146
Clinical Medicine

Prediction of the Course of Multiple Sclerosis Based on the Clinical Features of the Debut in Patients of the Poltava Region

Pinchuk V. A., Delva M. Yu., Hryn K. V.
Abstract

The purpose of the study was to demonstrate the importance of studying variants of the debut of multiple sclerosis, to reveal the dependence of the rate of progression on the clinical picture of the debut of multiple sclerosis by examining patients and retrospective analysis of clinical data. Materials and methods. The study analyzed 60 cases of relapsing-remitting and secondary-progressive multiple sclerosis in patients who were undergoing inpatient treatment in the neurological department of the communal enterprise “M. V. Sklifosovskyi Poltava Regional Clinical Hospital of the Poltava Regional Council” from 2019 to 2021. Complaints, anamnestic data, results of a complex clinical and neurological examination of patients with multiple sclerosis at the onset and throughout the course of the disease were studied. The diagnosis was established according to Mac-Donald criteria. The severity of clinical manifestations was assessed using the Extended Disability Scale. Results and discussion. The rate of disease progression was assessed retrospectively. The ratio of the number of the Extended Disability Scale points at this moment to the duration of the disease in years was studied. In the group of patients with a monosymptomatic debut, the rate of progression was: 0.64 in women, 1.2 in men. In patients with an acute polysymptomatic onset, the values of the rate of progression were 0.7 and 2.1, respectively. As a result of the retrospective analysis, several options for the onset of multiple sclerosis were identified: monosymptomatic, polysymptomatic, patients with a radiologically isolated syndrome, and patients with a characteristic clinical picture, but without pathological changes on magnetic resonance imaging. One of the most frequent clinical manifestations of the debut in patients in the Poltava region was sensitive disorders. It is worth noting that special attention should be paid to the study of vibration sensitivity. When collecting anamnestic data, it is necessary to clarify the presence of Lhermitte syndrome. The rate of progression of multiple sclerosis was found to be higher in male patients with polysymptomatic onset and motor disturbances, between the first symptoms (patient complaints) and the diagnosis of multiple sclerosis from 3 months to several years. Conclusion. The presented research results can be useful for neurologists, general practitioners, radiologists and doctors of other specialties for early diagnosis, prescribing pathogenetic treatment of multiple sclerosis and predicting its course. Prospects for further research are related to the monitoring of clinical observations of multiple sclerosis with the aim of improving diagnostic, therapeutic and rehabilitation measures

Keywords: multiple sclerosis, debut of the disease, progression rate

Full text: PDF (Ukr) 266K

References
  1. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018 Dec; 31(6):752-9. PMID: 30300239. https://doi.org/10.1097/WCO.0000000000000622
  2. Howard J, Trevick S, Younger DS. Epidemiology of Multiple Sclerosis. Neurol Clin. 2016 Nov;34(4):919-939. PMID: 27720001. https://doi.org/10.1016/j.ncl.2016.06.016
  3. Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy. Rozsiianyi skleroz [Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care. Multiple sclerosis]. 2016. [Ukrainian]
  4. PInchuk VA, Krivchun AM, Silenko GYa. Mistse olatropilu v likuvannya kognitivnih rozladiv u patsientiv iz rozsiyanim sklerozom [The place of olatropil in the treatment of cognitive disorders in patients with multiple sclerosis]. Ukrayinskiy visnik psihonevrologiyi. 2018;2(95):22-5. [Ukrainian]
  5. Voloshyn PV, Voloshyna NP, Taitslin VY. Rozsiianyi skleroz v Ukraini: rozpovsiudzhenist, perebih, prohnoz, likuvannia, farmakoekonomika [Multiple sclerosis in Ukraine: prevalence, course, prognosis, treatment, pharmacoeconomics]. Ukrainskyi visnyk psykhonevrolohii. 2007;1(50):6-21. [Ukrainian]
  6. Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, et al.Vascular comorbidity is associated with more rapid disability progression inmultiple sclerosis. Neurology. 2010 Mar;(74):1042-47. PMID: 20350978. PMCID: PMC2848107. https://doi.org/10.1212/WNL.0b013e3181d6b125
  7. Quispe-Cabanillas JG, Damasceno A, von Glehn F, Brandão CO, Damasceno BP, Silveira WD, et al. Impact of electroacupuncture on quality of life for patients with relapsing-remitting multiple sclerosis under treatment with immunomodulators: a randomized study. BMC Complement Altern Med. 2012 Nov 5;12:209:1-7. PMID: 23126260. PMCID: PMC3565890. https://doi.org/10.1186/1472-6882-12-209
  8. Sokolova LI. Suchasni kryterii diahnostyky rozsiianoho sklerozu v praktychnii nevrolohii [Modern criteria for the diagnosis of multiple sclerosis in practical neurology]. Ukrainskyi visnyk psykhonevrolohii. 2017; 25(1):106-7. [Ukrainian]
  9. Kurtzke JF. Rating neurologic impairment in Multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33:1444-1452. PMID: 6685237. https://doi.org/10.1212/WNL.33.11.1444
  10. Kamińska J, Koper OM, Piechal K, Kemona H. Multiple sclerosis – etiology and diagnostic potential. Postepy Hig Med Dosw (Online). 2017 Jun 30;71(0):551-563. PMID: 28665284. https://doi.org/10.5604/01.3001.0010.3836
  11. Klineova S, Lublin FD. Clinical Course of Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a028928. PMID: 29358317. PMCID: PMC6120692. https://doi.org/10.1101/cshperspect.a028928
  12. Cavenaghi VB, Dobrianskyj FM, Olival GSD, Carneiro RPCD, Tilbery CP. Characterization of the first symptoms of multiple sclerosis in a Brazilian center: cross-sectional study. Sao Paulo Med J. 2017 May-Jun;135(3):222-225. PMID: 28746657. https://doi.org/10.1590/1516-3180.2016.0200270117
  13. Horenynskaia SV, Zhestykova MH, Vasenyna ED, Komyssarova SD, Kolotova LH, Korotkevych NA, et al. The impact of the onset of multiple sclerosis on the prognosis of the course of the disease. Med Kuzb.2014;3:43-6.